Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Operating Margin: 2020-2025

Historic Operating Margin for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to 9.05%.

  • Xeris Biopharma Holdings' Operating Margin rose 3281.00% to 9.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.68%, marking a year-over-year increase of 2779.00%. This contributed to the annual value of -16.57% for FY2024, which is 1028.00% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Operating Margin stood at 9.05%, which was up 44.44% from 6.27% recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Operating Margin peaked at 9.05% during Q3 2025, and registered a low of -289.55% during Q2 2021.
  • Its 3-year average for Operating Margin is -16.11%, with a median of -17.03% in 2024.
  • Its Operating Margin has fluctuated over the past 5 years, first plummeted by 7,408bps in 2021, then skyrocketed by 21,480bps in 2022.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Operating Margin stood at -225.26% in 2021, then surged by 17,949bps to -45.77% in 2022, then skyrocketed by 2,360bps to -22.17% in 2023, then spiked by 2,496bps to 2.79% in 2024, then spiked by 3,281bps to 9.05% in 2025.
  • Its last three reported values are 9.05% in Q3 2025, 6.27% for Q2 2025, and -5.14% during Q1 2025.